U.S. patent application number 13/223611 was filed with the patent office on 2012-02-02 for absorbable implants and methods for their use in hemostasis.
This patent application is currently assigned to Orthocon, Inc.. Invention is credited to Richard L. Kronenthal.
Application Number | 20120027817 13/223611 |
Document ID | / |
Family ID | 34434873 |
Filed Date | 2012-02-02 |
United States Patent
Application |
20120027817 |
Kind Code |
A1 |
Kronenthal; Richard L. |
February 2, 2012 |
Absorbable Implants and Methods for Their Use in Hemostasis
Abstract
The present invention relates to mechanically hemostatic
body-absorbable compositions having a putty-like consistency
comprising a finely powdered polysaccharide and a biocompatible
liquid comprising one or more block copolymers of ethylene oxide
and propylene oxide.
Inventors: |
Kronenthal; Richard L.;
(Fair Lawn, NJ) |
Assignee: |
Orthocon, Inc.
Irvington
NY
|
Family ID: |
34434873 |
Appl. No.: |
13/223611 |
Filed: |
September 1, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10941890 |
Sep 16, 2004 |
|
|
|
13223611 |
|
|
|
|
60504978 |
Sep 23, 2003 |
|
|
|
Current U.S.
Class: |
424/400 ;
206/438; 514/54; 514/57 |
Current CPC
Class: |
A61L 24/0042 20130101;
A61L 2400/06 20130101; A61P 7/04 20180101; A61L 2400/04 20130101;
A61P 31/00 20180101; A61L 2430/02 20130101; A61L 24/08 20130101;
A61K 31/19 20130101; A61L 24/08 20130101; C08L 1/26 20130101 |
Class at
Publication: |
424/400 ; 514/54;
514/57; 206/438 |
International
Class: |
A61K 31/715 20060101
A61K031/715; A61B 19/02 20060101 A61B019/02; A61P 7/04 20060101
A61P007/04; A61K 31/717 20060101 A61K031/717; A61K 9/00 20060101
A61K009/00 |
Claims
1-293. (canceled)
294. A body-absorbable, mechanically hemostatic putty composition
comprising Components 1 and 2 wherein Component 1 is a finely
powdered polysaccharide and Component 2 is a biocompatible liquid
comprising one or more block copolymers of ethylene oxide and
propylene oxide, wherein Component 1 is 5-80% by weight of the
final composition and Component 2 is 10-70% by weight of the final
composition.
295. The composition of claim 294, wherein the polysaccharide of
Component 1 is selected from carboxymethyl cellulose and oxidized
cellulose.
296. The composition of claim 294, wherein the composition is
sterile.
297. The composition of claim 294, further comprising demineralized
bone matrix.
298. The composition of claim 294, further comprising an
anti-infective agent or a colorant, or both.
299. The composition of claim 294, wherein the average particle
size of the finely powdered polysaccharide is below 25 microns.
300. The composition of claim 294, wherein Component 1 is 20-50% of
the composition by weight.
301. The composition of claim 300, wherein Component 1 is
carboxymethyl cellulose.
302. A package comprising the composition of claim 294, wherein
said composition is sealed in an aseptic barrier package, and is
sterile or sterilizable.
303. The package of claim 302, wherein the composition is in an
amorphous form or in a generally rounded form, or in a generally
parallelepiped form.
304. The package of claim 302, wherein the package comprises a
plunger or applicator whereby said composition is expellable from
said package by the application of mechanical pressure applied to
the plunger or applicator.
305. The package of claim 302, wherein the package comprises a
squeezable, deformable tube having an openable exit port whereby
said composition is expellable from said tube by the application of
mechanical pressure thereto.
306. A method for mechanically controlling the bleeding of bone
which comprises applying an effective amount of the composition of
claim 294 to the affected area.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. provisional
application No. 60/504,978 filed Sep. 23, 2003
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] (Not Applicable)
REFERENCE TO A SEQUENCE LISTING, A TABLE, OR A COMPUTER PROGRAM
LISTING APPENDIX SUBMITTED ON COMPACT DISC (SEE 37 CFR
1.52(e)(5))
[0003] (Not Applicable)
BACKGROUND OF THE INVENTION
[0004] 1. Field of the Invention
[0005] The invention relates to the management, treatment, therapy,
and beneficial control of osseous conditions such as hemorrhage and
defects, through the use of materials having various viscosities,
cohesive strengths, and consistencies, most particularly putty-like
materials as well as creams, pastes, ointments, lotions, and gels.
More particularly, various novel, surgically implantable,
absorbable formulations, which may contain absorption accelerants,
bone growth-inducing materials, anti-infective or anti-neoplastic
agents to reduce the risk of infection or tumor growth,
respectively, analgesics, anti-inflammatory agents, clot-inducing
agents such as vasoconstrictors and styptic materials, are used as
bone hemostatic devices and/or as bone healing or therapeutic
adjuvants. The compositions also may contain radiopaque materials
and colorants.
[0006] 2. Description of Related Art
[0007] Cancellous and cortical bone contains relatively vascular
tissues that bleed when their vasculature is disrupted. Thus, when
bone is surgically incised or fractured traumatically, e.g., in
open or compound fractures, there are at least two major issues
which must be medically resolved. The first of these is the
occurrence of osseous hemorrhage. When osseous hemorrhage ensues,
it must be stopped or effectively controlled (hemostasis) to
prevent adverse surgical consequences. The second issue is that of
bone growth to promote healing (osteogenesis) of the traumatized
bone. Common procedures in which bone is surgically cut include
open-heart surgery involving the splitting of the sternum,
orthopedic and spinal surgery including hip implants, neurosurgery
involving spine or cranial incisions, amputations, trauma
treatment, and many other procedures.
[0008] At the present time, bone hemostasis is achieved by one or
more of (i) manually impregnating the bleeding surface with
commercially available, non-absorbable "bone wax", (ii) the use of
various hemostatic agents such as oxidized cellulose or
microcrystalline collagen and (iii) electrocautery. None of these
techniques promotes osteogenesis to any significant extent. In
addition to the unmet need for an effective, rapidly absorbable
bone hemostatic material, there is also a surgical need for
materials to fill bone defect voids and promote healing in such
cavities. A variety of paste-like materials, presently available to
the surgeon for this purpose, most commonly are based upon coarsely
powdered, demineralized allogeneic bone, suspended in a suitable,
biocompatible vehicle. These compositions are designed for inducing
osteogenesis and healing in the defect but, because of their
consistency, non-cohesiveness and other attributes of their
composition, they do not reliably adhere to injured bone and are
not effective hemostatic agents.
[0009] There are two major bodies of prior art concerned with bone
hemostasis and bone healing, respectively. As discussed below, up
to the present time, in the main, only products based upon
plasticized non-absorbable waxes have been available to the surgeon
for bone hemostasis. The disadvantages of makeshift devices
employing, for example, oxidized cellulose as well as the
tissue-destructive use of electrocautery (discussed below) are not
satisfactory alternatives.
[0010] The first body of art is directed specifically to bone waxes
which are manually pressed into the pores of the bleeding bone
surface, act as an effective mechanical tamponade, and prevent
blood from escaping. Presently available bone waxes consist of
mixtures of non-absorbable components such as bee's wax, paraffin,
petrolatum, fatty ester plasticizers, and the like. These products
must be warmed before use and become soft, kneadable and spreadable
by the surgeon onto and into cut bone surfaces. Because available
bone waxes are not absorbable and reside indefinitely where they
are placed by the surgeon, they act as permanent physical barriers
that inhibit osteogenesis, thereby preventing or slowing bone
healing. In addition, such a site acts as a perpetual postoperative
nidus for infection. If such infection does occur, it is usually
chronic and difficult to treat using conventional anti-infective
therapy and re-operation, to surgically excise the infected site,
often becomes necessary. For these reasons, commercially available
bone waxes do not enjoy widespread orthopedic use.
[0011] Other products or techniques used in this application
include oxidized cellulose products indicated for soft tissue
hemostasis, e.g., Surgicel.RTM., which are absorbable and would not
be expected to induce the complications cited above for bone wax.
However, they are not effective hemostatic products for bone
because of their inappropriate physical form (knitted fabric) and
are too difficult to use effectively on cut bone because of lack of
adherence within the bone pores.
[0012] The use of electrocautery, which thermally sears oozing
blood vessels closed, is time-consuming and produces widespread
tissue damage which may delay osteogenesis as well as allow soft
tissue in-growth that interferes with normal bone union, presenting
difficult problems for orthopedic surgeons in general and spine
surgeons in particular.
[0013] Collagen in various forms, alone or in combination with
fibrin and suspended in various delivery vehicles has been proposed
as a bone hemostatic agent but problems with, for example, storage
stability, cohesiveness, and biocompatibility have prevented
practical fruition.
[0014] The adaptation of synthetic absorbable polymers to this
application has not succeeded, apparently because of technical
difficulties in suitably formulating hydrolytically unstable
synthetic absorbable polymers into practical products with
reasonable package shelf life, useful handling properties and
acceptable biocompatibility and absorption rates.
[0015] The second body of prior art primarily is concerned with
bone healing and the treatment of bone defects. The bone healing
prior art compilation primarily describes the development of
biocompatible, absorbable vehicles to deliver and support processed
particulate allogeneic bone as it is applied to defects such as
excised cavities. These liquid or paste-like vehicles consist of a
variety of polyhydroxy compounds, ester derivatives of polyols,
hydrogels, and the like, sometimes containing additives to increase
the viscosity of the vehicle (to retard dissipation of the vehicle
and, thereby, extend the cohesiveness of the implanted mass) or
factors to induce new bone growth. Anti-infective, anti-tumor and
other additives also are described for these products. In no
instances are these compositions indicated for, act as, or
described in the art and claimed as bone hemostatic agents.
A. Bone Hemostasis
[0016] Attempts at providing absorbable bone hemostatic agents have
not been completely successful. An absorbable bone sealant
comprising fibrin and collagen (British Patent 1,584,080) requires
mixing in the operating room. A reportedly hemostatic dispersion of
microfibrillar collagen in polyethylene glycol (U.S. Pat. No.
6,117,444) loses coherence too rapidly as the glycol is dissipated.
A microcrystalline collagen lyophilized sponge (U.S. Pat. No.
6,454,787), designed for soft tissue hemostasis, is not as
well-suited for bone bleeding control. A hemostatic agent employing
polylactide (U.S. Pat. No. 4,186,448), lactide/glycolide oligomers
(U.S. Pat. Nos. 5,143,730, 6,420,454), moldable polymer blends
(U.S. Pat. No. 5,641,502), absorbable, hydrogel-forming synthetics
(U.S. Pat. No. 6,413,539) are not easily adapted to bone
hemostasis. Polydioxanone (U.S. Pat. No. 4,443,430) synthetic
absorbable polymer materials are difficult to employ because of
their relative instability in biocompatible, protonic delivery
vehicles. Another absorbable polyester such as a caprolactone
polymer (U.S. Pat. No. 6,485,749) has been described as a
replacement for bone wax.
[0017] A system with putty-like consistency at room temperature
(U.S. Pat. No. 4,568,536), preferably combining a fatty acid salt,
e.g., calcium stearate, an absorption enhancer, e.g., dextran and a
vehicle, e.g., castor oil was developed as an absorbable,
biocompatible matrix for the delivery of antibiotics, e.g.,
meclocycline sulfosalicylate, and other pharmacologically active
agents to treat periodontal diseases. However, this technology,
together with similar absorbable compositions, described in U.S.
Pat. No. 4,439,420 and U.S. Pat. No. 4,650,665, are deficient
because they are designed for drug delivery over extended
absorption time periods not thought optimal for rapid bone healing
and because they contain dextran, a polysaccharide presently
believed to be a toxicologically unacceptable implant material.
B. Bone Defect Healing
[0018] Materials designed for bone defect healing (but not
hemostasis) are based upon pulverized cortical and/or cancellous
allogeneic, demineralized, osteogenic bone powder, having particle
sizes usually between 1 and 12 mm, in a biocompatible carrier
selected from the group consisting of polyols, e.g., glycerol and
polyol derivatives, e.g., glycerol monoacetate (U.S. Pat. No.
5,073,373, U.S. Pat. No. 5,484,601). Many additives are cited for
this composition, e.g., anti-infective and anti-tumor agents,
surfactants, vitamins, endocrine tissue, etc. A variant of this
technology (U.S. Pat. No. 5,284,655) requires an increase of at
least 10% in the volume of the demineralized bone component after
contact with a swelling agent. The biocompatible suspending agent
for the swollen demineralized bone particles is selected from the
group including polyols and their esters, sucrose, polysaccharides,
alginic acid, amylose, agar, etc. A further aspect of the 5,073,373
patent (U.S. Pat. No. 5,290,558) provides a flowable powder and
claims large numbers of natural and synthetic polyhydroxy materials
and their ester derivatives as vehicles for demineralized bone
powder with a variety of additives such as BMP, IGF-1,
anti-infective agents, hydroxyapatite, surfactants, bioerodable
polymers and a variety of thickening agents such as PVA, PVP, CMC,
gelatin, dextran, collagen, polyacrylate salts, etc. To improve
handling characteristics of bone defect fillers (U.S. Pat. No.
5,314,476), particularly implant adhesion after the suspending
vehicle is dissipated, demineralized bone particles of relatively
high (10:1) median length to median thickness ratios are suspended
in vehicles cited in the '558 patent. In an entirely different
approach (U.S. Pat. No. 6,030,635), powdered demineralized bone
carriers, based upon aqueous solutions of polyelectrolytes such as
sodium hyaluronate, chitosan and N,O-carboxymethyl chitosan, are
claimed. These viscous, high molecular weight hydrogels may contain
anti-infective and other additives. A variant of U.S. Pat. No.
6,030,635 (U.S. Pat. No. 6,437,018) includes the addition of a
sodium phosphate buffer to form a more viscous hydrogel carrier for
smaller particle sizes of mineralized or demineralized bone.
[0019] A recently issued patent (U.S. Pat. No. 6,565,884) describes
a composition based on suspended demineralized bone matrix in
lecithin or in lecithin containing unsaturated triglycerides, e.g.
corn oil. The product is said to induce bone growth. However, it is
probable that the surface-active composition may easily be washed
away after implantation. In yet another attempt to provide a useful
material to stimulate new bone formation (U.S. Pat. No. 6,576,249),
methods are described in which demineralized bone matrix is
dissolved in water to form a viscous solution to which is added
mineralized or demineralized bone matrix particles that form a
water soluble, gel-like suspension.
[0020] As mentioned previously, in a search for a system to act as
a matrix for the controlled delivery of various drugs, primarily
for the treatment of periodontal diseases, workers developed
absorbable, biocompatible, putty-like compositions that adhered to
bone (teeth), were conformable at room temperature and easily
applied (U.S. Pat. No. 4,568,536). While the primary objective of
this composition was for prolonged drug delivery, the system was
based largely upon earlier disclosed putty-like compositions
specifically developed as bone hemostatic agents (U.S. Pat. No.
4,439,420).
[0021] The compositions described in U.S. Pat. No. 4,439,420 are
based essentially upon combinations of three types of materials; a
fatty acid salt, preferably calcium stearate, a fluid base,
preferably castor oil, and an absorption accelerator, preferably
dextran. This preferred composition, when tested for absorbability
as an intramuscular implant, was described as taking approximately
four weeks to absorb. No information or data concerning efficacy as
a hemostatic device were presented and apparently no experiments
were done to determine the absorption rate of the material when
actually used as a bone hemostatic device. Absorption from the
enclosed interstices of bone trabeculae would be expected to be
significantly slower than absorption from the more anatomically
"open" intramuscular site used as a model.
[0022] The 4,439,420 patent discloses alternatives for the three
preferred ingredients. Alternatives to calcium stearate are
magnesium, zinc, aluminum, lithium and barium salts of saturated
and unsaturated fatty acids containing from 10 to 22 carbon atoms
(collectively, fatty acid salts). Alternatives to castor oil are
ethylene oxide/propylene oxide block copolymers, polyethylene
glycols, methoxy polyethylene glycols, triglycerides, fatty acid
esters, sesame oil, almond oil, cottonseed oil, corn oil, olive
oil, cod liver oil, safflower oil and soya oil (collectively
molecules which, admixed with the fatty acid salt, form the slowly
absorbable putty-like mass). Alternatives to dextran are
Carbowax.RTM., the Pluronics.RTM., glycerine and propylene glycol,
which act as absorption accelerators by post-operatively absorbing
fluids and/or dissipating, thereby physically disrupting the
implant mass as it resides in tissue.
[0023] The primary reasons the 4,439,420 putty-like compositions
are unsuited for bone hemostasis are that the material, while
eventually biodegradable, is absorbed too slowly and, thus,
inhibits new bone growth infiltration and healing by acting as a
physical barrier, much as do the nonabsorbable, paraffin-based bone
waxes. In addition, the preferred composition described in the
patent contains a component, i.e., dextran, which is not acceptable
toxicologically. Finally, 4,439,420 compositions are "completely
free of fibrous materials" which may be a significant disadvantage
for optimum osteogenesis, a desirable characteristic for a bone
hemostatic device. The addition of agents such as demineralized
bone, bone growth factors and fibrous collagen to enhance
osteogenesis and healing and anti-infectives to inhibit infection
are not disclosed in the 4,439,420 patent.
BRIEF SUMMARY OF THE INVENTION
[0024] The formulations of the present invention are compositions
having various viscosities and cohesive strengths and include putty
and non-putty formulation consistencies.
[0025] The term "putty" is used herein as it is used in the art and
is generally known to the skilled artisan. Dough (such as pastry
dough), modeling clay, and glazier's putty of varying viscosities,
depending on the indications and ultimate use, are examples of the
consistency of a suitable product. Putties of various viscosities
useable in the invention include those that are capable of adhering
to bone. In general, putties which are soft, moldable, preferably
non-elastic, cohesive mixtures prepared from a finely powdered
substance intimately admixed with a liquid dispersing vehicle and
having a shape which is capable of being deformed in any direction,
are suitable consistencies for the putty-like compositions of the
invention. As will be described later, however, compositions which
have lower cohesive strengths than the putties described above, are
within the scope of the invention, and may be used in specific
applications in which the more viscous, higher cohesive strength
putties are less suitable. For purposes of this invention, a major
difference between putties of the invention and materials not
considered to be putties (i.e. non-putties), but which are still
within the scope of the invention, is that the non-putties have
lower cohesive strengths than the cohesive strengths of the putty
formulations. Individual non-putties of the invention are
characterized by having the cohesive strength of creams, pastes,
ointments, lotions, foams, gels, whipped egg whites, whipped cream,
and the like. Preferably, the non-putties have only a fraction of
the cohesive strength of putties of the invention, tending to be
easily collapsible or easily torn apart under small stresses that
would not, generally speaking, have the same effect on putties. The
description which follows is given mainly in the context of the
putties of the invention, it being understood, however, that if
less cohesive strength materials are desired, the skilled artisan
will simply make the appropriate changes in the proportions of
components or add other substances to achieve the same purpose.
[0026] The present invention involves formation of medically useful
absorbable putty-like and non-putty-like compositions using
dispersing vehicles not previously reported for preparing such
materials, intimately admixed with finely powdered bulking agents,
some of which have been previously used, but not with the present
dispersing vehicles, and some of which have not heretofore been
used, in preparing such putty-like and non-putty-like
compositions.
[0027] A sterile, absorbable bone hemostatic agent, that is, a
material that will provide virtually immediate surgical hemostasis
and also will absorb in the body after a relatively short period of
time without compromising hemostasis efficacy, would have
significant medical advantages over presently available materials.
It would minimally inhibit osteogenesis and subsequent bone
healing. Moreover, bone-healing adjuvants such as growth factors,
particularly, for example, platelet derived growth factor (PDGF)
and/or bone morphogenic proteins (BMPs) and others, could be added
to the formulations to stimulate the bone healing process.
Furthermore, adding agents such as collagen, demineralized bone
matrix (DBM), and/or hydroxyapatite could make the hemostatic
material beneficially osteoconductive and osteoinductive. The
addition of a suitable anti-infective agent such as antibiotics
typified by tobramycin and gentamicin or bacteriostatic and
bacteriocidal materials such as iodine, silver salts, colloidal
silver, or the like serve to reduce the potential for infection,
particularly in contaminated open wounds such as compound
fractures. The addition of colorants would aid in visibility during
the operative procedure. The addition of radiopaque substances
allows the observation of post-operative sequelae using
radiography. The addition of chemotherapeutic agents or
radionuclides is useful when the putty is used, for example, in
bone cavities arising from tumor resection. Analgesic compounds to
reduce pain, and vasoconstrictors and blood clot-inducing agents to
reduce hemorrhage, are useful additives.
[0028] The novel and inventive concepts described below for the
preparation of the products of the present invention include at
least two components, Component 1 being a bulking agent and
Component 2 being a dispersing vehicle which, when intimately
admixed with the bulking agent in appropriate proportions, yields a
base for products of the invention. The selection of a suitable
Component 2 will result in a composition that is absorbed by the
body within an acceptable period of time. In such a case, Component
2 will act as its own absorption accelerant and the formulation
will not require a separate absorption accelerant. If desired,
however, the composition of the invention also may be provided with
an optional ingredient which serves to accelerate the absorption of
the putty by the body.
[0029] The invention provides implantable, appropriately
absorbable, biocompatible, putty-like compositions that are useful
as mechanical hemostatic tamponades for the control of osseous
hemorrhage arising from surgical intervention or trauma and for
providing an osteoinductive matrix to foster improved bone
healing.
[0030] Accordingly, one aspect of the invention provides
sterilizable putty-like compositions of matter and methods for
their use comprising the step of physically pressing the putty-like
compositions into the bleeding area of bone, thus mechanically
staunching bleeding, after which the composition is absorbed and
harmlessly eliminated from the body.
[0031] In another aspect, particularly useful in, but not
necessarily limited to, traumatically opened wounds, an
anti-infective agent is added to, and then post-operatively
released from, the putty-like composition to inhibit the occurrence
of postoperative infection.
[0032] In another aspect, the invention provides for adding to the
art-known non-absorbable or slowly absorbable bone hemostatic
materials, one or more of mineralized or demineralized bone
particles, collagen, hydroxyapatite, bone morphogenic protein
and/or other bone growth factors to form a novel putty-like
composition for the dual purpose of providing initial hemostasis
and then stimulating new bone formation.
[0033] In another aspect, the invention provides for the addition
of an anti-infective agent to the putty-like composition containing
bone growth stimulating additives to inhibit the occurrence of
postoperative infection.
[0034] The anti-infective agent, which may be an antibiotic, a
bacteriostatic or a bacteriocidal material, may be added to the
putty-like mass or may be reversibly bound to additives, e.g.
gelatin or collagen, which are to be contained within the putty.
For example, using iodine as the anti-infective agent, a complex of
iodine with gelatin, collagen or PVP may be used. In addition,
colloidal silver, silver salts, or silver complexes with gelatin or
other polymers may be used. Still further, antibiotics, in addition
to being capable of being added to the putty as described above,
may be added as part of a delivery system, preferably as part of a
component of the putty. In particular, gentamicin, bound to
powdered collagen, is an example of a useful antibiotic release
system. Similarly, anti-neoplastic agents may be added to the
putty-like composition in the same manner, preferably as a free
agent, to provide an effective anti-tumorigenic material.
Analgesics to reduce pain, blood clot-inducing agents to act as
chemical hemostatic agents, and anti-inflammatory agents, may also
be added. Furthermore, radiopaque components may be added to allow
radiographic observation and colorants to improve intra-operative
performance.
[0035] Additional objects, features and advantages will be apparent
in the written description that follows.
DETAILED DESCRIPTION OF THE INVENTION
[0036] The compositions of the present invention include
compositions comprising at least two and preferably three, four, or
more components. They are most preferably body absorbable. In many
embodiments they have a putty-like consistency. In one embodiment,
the compositions are mechanically hemostatic tamponades useful in
stopping the bleeding of bone by the application of the putty-like
composition to the affected area. By "mechanically hemostatic
tamponades" is meant that the compositions function by mechanically
compressing the bleeding areas of the bone to arrest hemorrhaging
as opposed to functioning by chemically hemostatic means, i.e. the
arresting of hemorrhaging, in whole or in part, using a chemical
means. In another embodiment, the compositions, in addition to
being mechanically hemostatic, are also osteogenic in that they
contain an added ingredient, i.e. a bone growth-inducing material,
to aid in the induction of bone growth. Of the at least two
components mentioned in the first sentence of this paragraph,
Component 1 is a finely powdered bulking material having an average
particle size sufficiently small to form a putty-like consistency
when intimately admixed with the second component, i.e. dispersing
vehicle Component 2 of the invention. Illustrations of Component 1
are hydroxyapatite, a carboxylic acid salt, preferably a fatty acid
salt such as calcium stearate or a homolog thereof such as calcium
laurate, or other finely powdered agents such as synthetic
absorbable polymers, e.g. polyglycolide, polylactide, co-polymers
of lactide and glycolide, polydioxanone, polycaprolactones, as well
as absorbable glasses, (such as those based upon phosphorus
pentoxide and the like). The Component 2 dispersing vehicle is a
liquid which, when intimately admixed with Component 1, enables the
formation of the putty-like implant. While the two-component
compositions of the invention provide the basic characteristics of
suitable hemostatic materials as described herein, they may also,
but are not required to, contain, if desired, optional ingredients
3 through 12, shown below. For example, optional Component 3 is an
absorption accelerator, and Optional Component 4 is a bone
growth-inducing material. Other components may be added to provide
additional attributes to the putty-like and non-putty like
compositions of the present invention as will be explained in more
detail below.
[0037] Following is a detailed description of the various
components.
Component 1
[0038] Component 1 is comprised of a finely powdered, preferably
micronized, biocompatible, body-absorbable substance which, when
admixed with a liquid dispersing vehicle, Component 2, forms the
compositions of the invention. Suitable compositions are obtained
when the average particle sizes of Component 1 materials are about
50 microns or less, but the preferred average particle size range
is between about 3 to about 25 microns and most preferably about 6
to about 15 microns especially when putty-like compositions are
desired. Particle sizes for non-putty compositions may range higher
than those of the putty compositions, if desired.
[0039] Examples of one set of materials suitable for use herein are
salts of one or more carboxylic acids having a carboxylate anion
and a metal cation, some which are known in the art, having been
described in U.S. Pat. Nos. 4,439,420 and 4,568,536. Suitably, the
salts may be the calcium, magnesium, zinc, aluminum, lithium or
barium salts of saturated or unsaturated carboxylic acids
containing about 6 to 22 carbon atoms in the chain and preferably 8
to 20 carbon atoms. The preferred saturated carboxylic acids
supplying the carboxylate anion may be selected from aliphatic
acids such as caprylic acid, capric acid, lauric acid, myristic
acid, palmitic acid, stearic acid, arachidic acid, and intervening
homologs thereof, but the most preferred acids are the higher fatty
acids such as lauric, myristic, palmitic, and stearic acids, with
stearic being most preferred. Calcium and aluminum palmitates and
stearates are preferred salts with calcium stearate being most
preferred because of its excellent safety profile, and
putty-forming characteristics. However, aluminum stearate, aluminum
palmitate, or aluminum laurate, are suitable as well.
[0040] Examples of suitable unsaturated aliphatic acids which may
be used for supplying the carboxylate cation are oleic acid and
linoleic acid for which the same cations described above are
used.
[0041] It has been discovered that finely divided materials, for
example, about 50 microns or less, other than carboxylate salts,
can be effective Component 1 substances. For example, it was
surprising to find that finely powdered hydroxyapatite (calcium
phosphate), especially when less than about 25 microns in average
particle size, formed an excellent putty, especially with
tocopheryl acetate as the liquid dispersing agent (Component 2).
Furthermore, other materials, some of which are discussed in
connection with Component 4, are useful as Component 1 when
provided in finely powdered form. Examples of these are
demineralized bone matrix (DBM), mineralized bone matrix (MBM),
insoluble absorbable collagens, gelatin derived from collagens,
monosaccharides, and polysaccharides. It is thought that any
biocompatible material, when converted to very small particle
sizes, will form medically useful compositions. It would not be
uncommon, when producing compositions of the present invention, to
have, for example, hydroxyapatite particles of 6-12 microns as
Component 1, a suitable Component 2, with or without a suitable
component 3 such as gelatin, and bone chips such as a demineralized
bone matrix or a mineralized bone matrix having a particle size of
about 0.5 to about 1 mm or larger as Component 4. Other examples
are finely milled synthetic absorbable homo- and co-polymers, e.g.,
polyglycolide, polylactide, copolymers of lactide and glycolide,
polydioxanones, polycaprolactones, copolymers of dioxanone and of
caprolactone and of trimethylene carbonate, gelatins,
monosaccharides such as glucose and mannose, and polysaccharides
such as carboxymethyl cellulose and oxidized cellulose typified by
Surgicel.RTM., starches, sucrose, suitably in the form of
confectioner's sugar, alginic acid, hyaluronic acid, chitosan and
its acetyl derivatives, and the like, as well as absorbable
glasses, and the like. In addition, certain biologically active
materials such as bioglasses (discussed in more detail in
connection with Component 4 below), which may not be considered as
absorbable in the usual sense, can be used in finely powdered form
as Component 1. For example, absorbable polymers having an average
particle size below about 25 microns will form a useful, stable
absorbable hemostatic putty when mixed with, for example,
tocopheryl acetate or the triglyceride oils, especially the castor
oil, of U.S. Pat. No. 4,439,420. Thus, any natural or synthetic
absorbable polymer that can be reduced to sufficiently small
particle size will form a stable, absorbable putty if admixed with
a suitable, compatible vehicle.
[0042] It also has been discovered that absorbable glasses, based
upon phosphorus pentoxide (instead of silicon dioxide), and
containing alkali or alkaline earth metal oxides such as sodium,
potassium, calcium and magnesium oxides as the network polymer, are
slowly dissolvable in aqueous media and can be used as Component 1.
In addition, such compounds may be used as absorption accelerants,
i.e., as Component 3, in which case, they may, but need not, be
used in as finely powdered a form as when they are used as
Component 1. U.S. Pat. No. 4,612,923 refers to the preparative
prior art concerning these glasses as well as their application as
additives for strength reinforcement and stiffness enhancement for
synthetic absorbable surgical devices. When the 325 mesh glass
described in Example 1 of U.S. Pat. No. 4,612,923 is further
pulverized to average particle sizes below 50 microns, the
resulting fine powder forms a medically useful absorbable putty
when admixed with the vehicles described in U.S. Pat. No. 4,439,420
and in this specification. The rate of aqueous dissolution
(absorption) of such glasses can be increased by increasing the
proportion of alkali metal oxides and decreased by increasing the
proportion of alkaline earth metal oxides.
[0043] This novel approach, discussed above, i.e., forming useful
absorbable putties by drastically reducing the particle size of the
bulking vehicle Component 1, overcomes many of the difficulties of
the prior art, especially those of synthetic absorbable polymers as
bone hemostatic agents.
Component 2
[0044] As the second component, i.e., the material which is mixed
with Component 1 to obtain the composition of the invention, there
may be mentioned several classes of materials that have not been
heretofore employed as dispersing vehicles for preparing medical
putties. At the outset, it should be noted that Component 2 is
biocompatible and preferably a liquid because the liquid form
facilitates the admixture with Component 1 to form the putty or
non-putty mass. It will be appreciated, however, that Component 2
may also be a solid if a liquid vehicle (a liquefying agent, as
more fully discussed below) is used to act as a medium for
Components 1 and 2.
[0045] To aid in understanding the terms used herein and to help
differentiate this aspect of the invention from that of the prior
art, it would, perhaps, at this point, be useful to emphasize the
nature of the chemical entities referred to in this Specification
by briefly reviewing relevant classical chemistry terminology to
ensure the appropriate chemical distinctions are understood.
[0046] Carboxylic acids are substances defined by the attachment of
an OH group to a carbonyl function through a covalent bond. As a
result, carboxylic acids possess physical and chemical properties
totally distinct from substances containing either the carbonyl
functionality (e.g., aldehydes, ketones) or the hydroxyl
functionality (alcohols). The same distinction holds true for
substances containing both the carbonyl and hydroxyl groups not
directly attached through a covalent bond, such as hydroxyacetone,
which displays both ketone and alcohol properties, but not
carboxylic acid characteristics. Carboxylic acids always combine a
carbonyl and an OH group and have acidic characteristics, but the
OH group does not have the characteristics of the hydroxyl group of
an alcohol. A monocarboxylic acid would, therefore, not be
described as a monohydroxy compound. To illustrate this, consider
acetic acid and ethanol which are both two-carbon compounds
containing an OH group. In acetic acid, the hydrogen atom of the OH
group is liberated as an ion in water, whereas in ethanol, the
hydrogen atom of the hydroxyl group is not so liberated. Thus,
carboxylic acids dissociate and form carboxylate salts with bases,
e.g., calcium stearate, a distinctive property that clearly
differentiates the OH group of carboxylic acids from the hydroxyl
group of alcohols that do not dissociate to form salts with bases.
Thus, it would be entirely incorrect to characterize a carboxylic
acid as an alcohol, a monohydric alcohol, or some such term since
it is, in no chemical sense, an alcohol. Nor could a polycarboxylic
acid be referred to as a polyalcohol, or a polyhydroxy compound or
a polyol simply because it contains carboxylic OH groups. Such
groups are not characterized as alcohols. An example of these
distinctions is illustrated by considering the well-known molecule,
citric acid. This substance has three carboxylic groups and one
hydroxyl group in the same molecule. Citric acid is a monohydroxy
(monohydric) alcohol as well as a polycarboxylic acid. The fact
that citric acid contains three carboxylic OH groups does not
classify this monohydroxy compound as a polyhydroxy compound.
Because of the major differences in reactivity, synthesis and
reactions, in every textbook of organic chemistry, the chemistry of
alcohols always is considered in a separate chapter from the
chemistry of carboxylic acids.
[0047] Alcohols may be regarded either as hydroxyl derivatives of
hydrocarbons or as alkyl derivatives of water. They are typified by
the R--OH structure where R is an alkyl group. In contradistinction
to the readily ionizable hydrogen atom of the carboxylic acid
hydroxyl group, the R--OH hydrogen atom is virtually unionized in
water. On this basis, aliphatic alcohols are considered neutral
rather than acidic. One or more hydroxyl groups may be appended to
a hydrocarbon moiety so that, for example, propane may have one
hydroxyl group (propyl alcohol), two hydroxyl groups (propanediol
or propylene glycol) or three hydroxyl groups (propanetriol or
glycerol). Propylene glycol and glycerol are simple examples of
polyols. Polysaccharides, such as hyaluronic acid, contain many
hydroxyl groups on each monomer unit and are correctly termed
polyols. Alcohols may have short alkyl chains such as methyl
alcohol, ethyl alcohol, propyl alcohol, etc., or they may have
longer alkyl chains such as lauryl alcohol, myristyl alcohol, etc.
It is of critical importance to note that lauric acid
(C.sub.11H.sub.23COOH, a fatty acid) and lauryl alcohol
(C.sub.12H.sub.25OH, a fatty alcohol) are completely different
molecules in oxidation state and functionality, even though they
both contain twelve carbon atoms.
[0048] Esters are commonly derived from the reaction of a
carboxylic acid with an alcohol and can be converted back to the
original carboxylic acid and alcohol by hydrolysis. Thus, acetic
acid and ethyl alcohol are combined in the esterification process
to form ethyl acetate and water. The term fat (or vegetable or
animal oil) is confined to esters of a variety of long chain
saturated or unsaturated fatty acids with glycerine (glycerides).
Oils, cited in the prior art as vehicles for preparing putty-like
materials, are exclusively glycerides, e.g., castor oil, sesame
oil, olive oil, etc., as well as simple fatty acid esters such as
ethyl laurate. What never have been proposed in the prior art as
vehicles for preparing putty-like substances, are free liquid fatty
carboxylic acids such as the saturated caprylic acid and the
unsaturated oleic acid. Most important, the use of esters of fatty
alcohols with low molecular weight mono- or polycarboxylic acids,
e.g., lauryl acetate (the ester of lauryl alcohol and acetic acid)
are completely novel for the preparation of putty-like materials
and are chemically distinct from the prior art cited ethyl laurate
(the ester of Laurie acid with ethyl alcohol).
[0049] Returning now to the description of the Components of the
present invention, more particularly Component 2, the elements are
more specifically described as follows:
[0050] As a first class of Component 2, there are one or more
absorbable esters of a C.sub.8-C.sub.18 monohydric alcohol with a
C.sub.2-C.sub.6 aliphatic monocarboxylic acid. The monohydric
alcohols may be selected from C.sub.8-C.sub.18 alcohols such as
octyl alcohol, decyl alcohol, lauryl alcohol, myristyl alcohol,
stearyl alcohol, and intervening homologs thereof. The preferred
alcohols are the higher aliphatics such as lauryl alcohol, myristyl
alcohol, and stearyl alcohol. Illustrative of the useful esters
formed with the C.sub.2-C.sub.6 monocarboxylic acids are lauryl
acetate and myristyl propionate.
[0051] As a second class of Component 2, there are one or more
absorbable esters of a C.sub.2-C.sub.18 monohydric alcohol with a
polycarboxylic acid. The C.sub.2-C.sub.18 monohydric alcohols
include, in addition to the C.sub.8-C.sub.18 alcohols described in
the first class of esters there are the lower aliphatic,
C.sub.2-C.sub.8, alcohols such as ethanol, propanol, butanol,
pentanol, heptanol, hexanol, and octanol which yield the
corresponding ethyl, propyl, butyl, pentyl, heptyl, hexyl, and
octyl moieties. The polycarboxylic acids may be selected from
malonic, succinic, glutaric, adipic, pimelic, suberic, azelaic,
sebacic, maleic, fumaric, glutaconic, citric, malic acids, and
esters of the hydroxy function, if any, of the esterified
polycarboxylic acid, especially acetyl citric acid and acetyl malic
acids. It will be obvious to those skilled in the art that many
combinations of alcohol/acid esters may be selected from the above,
but the preferred ones for use in the invention from the monohydric
alcohol/polyacid esters are diethyl succinate, dioctyl succinate,
triethyl citrate, tributyl citrate, and higher and lower homologs
thereof, acetyl triethyl citrate, acetyl tributyl citrate and
higher and lower homologs thereof, butyryl triethyl citrate,
diethyl malate, di-pentyl malate, and acetyl diethyl malate, and
higher and lower homologs thereof.
[0052] Another class of materials, suitable as Component 2, are the
higher C.sub.8-C.sub.12 up to about C.sub.30 and preferably liquid
or liquefiable monohydric alcohols such as octanol and decanol. An
especially surprisingly suitable embodiment of this class is the
aromatic alcohol tocopherol (Vitamin E) in its optically active or
racemic forms and in any of the alpha, beta, gamma or delta forms,
as well as liquid tocopherol esters (sometimes referred to herein
as tocopherol esters) with a C.sub.2-C.sub.10 aliphatic
monocarboxylic acid, a polycarboxylic acid or mixtures thereof.
Useful are the tocopherol esters such as acetates, butyrates,
caproates, caprylates, caprates, and intervening homologs thereof,
and polycarboxylic acid ester such as those mentioned in the
previous paragraph, especially esters of succinic, citric, and
malic acids, with succinate being preferred.
[0053] Another class of materials, useful as Component 2, are
hydrocarbons having from about 10-14 carbons atoms. For example,
decane and dodecane are suitable.
[0054] Another class of materials, useful as Component 2, are the
liquid or liquefiable saturated or unsaturated, free carboxylic
acids such as the non-esterfied fatty acids, oleic, linoleic,
caprylic, capric, and lauric. In this class, the normally liquid,
saturated fatty acids would be suitable but may not be desirable
because of their unpleasant odor. Some low melting saturated
free-fatty acid mixtures that form a lower-melting eutectic mixture
which is liquid-at-room-temperature may also be suitable. One
advantage of saturated free-fatty acids lies in their improved
stability to radiation sterilization whereas the unsaturated acids,
e.g., oleic, may require radiation sterilization in an oxygen-free
container. Higher homologs of solid acids can also be used in
admixture with Component 1 in the presence of a liquefying medium
or other suitable component. Any compatible liquid may be used as
long as it ensures the liquefaction of Component 2 and is
biocompatible as well.
[0055] Another class of materials, useful as Component 2, are
ethers of the simple dialkyl ether class and alkyl aryl ether class
as well as cyclic polymers of alkylene glycol e.g., ethylene
glycol, known as crown ethers, all having boiling points greater
than about 80.degree. C. such as di-n-butyl ether, di-n-hexyl
ether, di-n-octyl ether, and unsymmetrical ethers such as ethyl
hexyl ether, ethyl phenyl ether, and the like, or, block copolymers
of ethylene oxide and propylene oxide in various ratios of ethylene
oxide to propylene oxide and various molecular weights, preferably
from 1000 to 10,000, (Pluronics.RTM.). They are available in liquid
or solid form. Illustrative of suitable materials are those shown
below in examples 42, 56, and 57. In addition to their suitability
for Component 2, they may also be used as an absorption accelerant
(Component 3). They are available under the trade name
Pluronics.RTM. from BASF Corp. Mt. Olive, N.J. 07828.
[0056] Another class of materials, useful as Component 2, are
symmetrical and unsymmetrical dialkyl ketones and alkyl aryl
ketones having boiling points greater than about 80.degree. C. such
as methyl propyl ketone, diethyl ketone, methyl butyl ketone, ethyl
propyl ketone, methyl pentyl ketone, and 2-octanone, 2-nonanone,
2-decanone, and methyl phenyl ketone.
[0057] Another class of materials useful as Component 2 are
selected from a member of the group consisting of polyhydroxy
compounds, polyhydroxy compound esters, solutions of polyhydroxy
compound, and mixtures thereof, and fatty acid esters. Preferred
among these are the liquid polyhydroxy compounds selected from the
group consisting of acyclic polyhydric alcohols, polyalkylene
glycols, and mixtures thereof. Specific examples of the foregoing
are ethylene glycol, diethylene glycol, triethylene glycol,
1,2-propanediol, trimethylolethane, trimethylopropane, erythritol,
pentaerythritol, polyethylene glycols, a liquid solution of a fatty
acid monoester of glycerol such as glycerol monolaurate. Solids
among the foregoing may be dissolved or dispersed in a suitable
solvent medium such as propylene glycol, glycerol, monoacetin,
diacetin, liquid polyethylene glycol, and mixtures thereof. As
glycerides, there may be mentioned monoglycerides, e.g., glyceryl
acetate, glyceryl stearate, homologs thereof, and the like,
diglycerides such as glyceryl diacetate, glyceryl dicaprate,
dibutyrate, dilaurate, and the like, and triglycerides such as
olive oil, castor oil, almond oil, sesame oil, cottonseed oil, corn
oil, cod liver oil, safflower oil and soya oil. It should be noted
that the foregoing polyhydroxy compounds may also be used, if
desired, as Component 3 absorption accelerants. If DBM powder is
present in the formulation (e.g., Component 1) then the polyhydroxy
compound may not be an acyclic polyhydric alcohol, non-reducing
sugar, sugar alcohol, sugar acid, monosaccharide, disaccharide,
water-soluble or water dispersible oligosaccharide, polysaccharide,
polyalkylene glycol or mixtures thereof.
[0058] As a statement of general applicability, it should be noted
that Component 2 materials which are liquid at room temperature are
the preferred substances for Component 2, and since they are
liquids, a liquefying agent is not necessary. Also useful as
Component 2 substances, however, are compounds which are solid at
room temperature. In such cases, especially when putties are
desired, a solid Component 2 is converted to a liquid form before,
during, or after admixture with Component 1 through the use of an
absorbable biocompatible liquefying agent capable of liquefying,
solubilizing a solid Component 2. By "liquefying agent" as used
herein, is meant an agent, such as a suitable solvent, which can
solubilize the solid, or any other agent even though the agent may
not be considered a solvent in the usual sense of that term, or an
agent which can liquefy the solid, such as heat, or which can
disperse the solid in a liquid as a dispersion so as to aid in the
formation of a homogenous putty, cream or paste-like mixture. The
particular agent used will, of course, depend upon the nature of
Component 2 used in the particular formulation. Suitable agents are
materials similar to Component 2 though not precisely described
herein as Component 2.
[0059] The foregoing novel concepts and compositions utilizing the
esters of monoalcohols with the mono- or polycarboxylic acids
described above, provide an absorbable bone hemostatic implant. The
novel utilization of relatively low molecular weight, non-toxic and
rapidly degradable simple esters such as diethyl succinate,
triethyl citrate and lauryl acetate have been found to provide
superior alternatives to the much higher molecular weight fatty
acid triglycerides, e.g., castor oil, for Component 2. This aspect
of the invention thus permits one to eliminate, if desired, both
the art-known version of Component 2, i.e. hydrophobic, slowly
absorbed esters such as the triglycerides typified by the
ricinoleic acid triglyceride, castor oil, as well as by fatty acid
esters such as isopropyl myristate and the need for the use of an
absorption accelerant.
[0060] These art-known putty compositions containing the art-known
Component 2 materials, such as those of U.S. Pat. No. 4,439,420
can, however, be used to obtain useful osteogenic bone hemostatic
materials in accordance with another aspect of the invention. It
has been discovered that, when it is desired to have a bone
hemostatic composition having osteogenic properties albeit with
slower absorption characteristics, the art-known composition may be
improved by the addition of osteogenic materials, e.g.,
demineralized bone matrix (DBM), mineralized bone matrix (MBM),
hydroxyapatite, or growth factors such as bone morphogenic protein
(BMP) and platelet derived growth factor (PDGF), as will described
below.
Component 3--Optional
[0061] The third component, usually a hydrophilic material, is
optionally included as an absorption accelerant and may even be
used to control the kinetics of absorption by physically assisting
in the disintegration of the implanted mass. Accelerants used in
the prior art may be used if they are not toxic or otherwise
bioincompatible. One or a combination of such prior art compounds
as Carbowax.RTM., the Pluronics.RTM., (See discussion under
Component 2 supra and discussion below) and glycerine, propylene
glycol, lecithin, betaine, and polyhydroxy compounds such as
hyaluronic acid, carboxymethylcellulose and chitosan and its acetyl
derivatives may be used as absorption enhancers in the compositions
of the invention, with the above caveat. It is preferred, however,
to use for this purpose, other materials which are swellable or
soluble and absorbable, such as either soluble or insoluble,
natural or synthetic polypeptides, exemplified by purified,
powdered insoluble fibrillar, but swellable collagens, the more
rapidly absorbable soluble tropocollagens such as Vitrogen.RTM. and
the more rapidly absorbable cold and hot water soluble
polypeptides, e.g. the gelatins. Lecithin and octylphenyl
ethoxylates, such as Triton.RTM. X 100, may be used as
biocompatible surfactants to aid in swellability.
Polyvinylpyrrolidone and other soluble, absorbable polymers such as
the block copolymers of ethylene oxide and propylene oxide
discussed supra in connection with Component 2, and relatively
hydrophilic polypeptides, e.g., polyaspartic acid, polyglutamic
acid, and their salts are also functional in this context. Most
preferably, the compositions of the present invention contain, as
the third component, insoluble, fibrillar collagen, soluble
collagen, gelatin, octylphenyl ethoxylates (e.g. Triton.RTM. X
100), the block copolymers of ethylene oxide and propylene oxide,
polyvinylpyrrolidone or absorbable phosphorus pentoxide-based
glasses or stable mixtures of the foregoing. Particle sizes in the
range of about 200-500 microns produce suitable results although
larger or smaller particle sizes may be employed depending on the
desires of the end user. Gelatin, PVP and other polymers have been
used in the demineralized bone art as thickening additives but not
as absorption accelerants. The thickening properties of gelatin
vary directly with the Bloom number of the gelatin. Gelatin having
Bloom numbers ranging from 100-300 are suitable in the compositions
of the invention, although values above or below those numbers may
be employed if the resulting product is acceptable to the end
user.
[0062] Illustrative of some suitable proportions of Components
which produce compositions having the properties described above,
are the following:
[0063] Component 1. From about 5 to 80%, preferably about 20 to 50%
by weight of the final composition.
[0064] Component 2. From about 10 to 70%, preferably about 20 to
50% by weight of the final composition.
[0065] Component 3. From about 0 to 80%, preferably about 10 to 70%
by weight of the final composition.
[0066] While the foregoing discussion has been presented largely in
the context of materials having the consistency of a putty in some
applications it may be desired to have a relatively less viscous or
less cohesive composition. For example, it may be desired to place
the composition of the invention into a void in the bone (drilled
or otherwise formed, e.g. hairline fractures) into which a putty of
high viscosity can be applied only with difficulty. A less viscous
form of the putty compositions of the invention would be a
desirable alternative. All one needs to do is modify the
proportions presented herein to allow for a higher liquid
concentration or add a compatible liquid diluent to achieve this
purpose. Using this approach, an injectable form of the material
can be obtained as well. Other less cohesive strength, non-putty
compositions, such as creams, ointments, gels, lotions, and the
like previously referred to, may be prepared in the same
manner.
Component 4--Optional
[0067] The products described above are suitable hemostatic
products which also will allow the growth of bone at the bone wound
site. Thus, they are osteoconductive. A desirable aspect of the
invention is to make the hemostatic product osteoinductive as well,
that is, to provide the product with Component 4, a bone
growth-inducing material (osteogenic material) in an amount
effective to induce bone growth. Thus, it has been found that the
inclusion of osteogenic materials such as growth factors, e.g.
Platelet Derived Growth Factor (PDGF), Transforming Growth Factor
beta (TGF-beta), Insulin-Related Growth Factor-I (IGF-I),
Insulin-Related Growth Factor-II (IGF-II), Fibroblast Growth Factor
(FGF), Beta-2-Microglobulin (BDGF II), bone morphogenic protein
(BMP), and combinations thereof stimulate osteogenesis to varying
degrees. Other bone growth-inducing materials such as demineralized
bone matrix (DBM), osteonectin, osteocalcin, osteogenin, and
combinations thereof, mineralized bone matrix (MBM), and/or
hydroxyapatite, a component of normal bone, as well as bioactive
glasses, render the hemostatic product suitably osteogenic.
Hydroxyapatite is an inorganic calcium phosphate mineral, prepared,
among other ways, synthetically or from sea coral (from which all
organic material has been removed), which has been demonstrated to
support the rapid in-growth of new bone tissue. Bioactive glasses
are finely powdered glass particles which are biocompatible. They
are useful as bone implant materials. A line of bioglasses is
available commercially as VITRYXX.TM. from Schott, GmbH, Mainz,
Germany. According to the manufacturer, when implanted into the
body, the surface remodels to form "hydroxy carbono-apatite" upon
which bone repair cells are deposited and form new bone tissue.
[0068] When used, a suitable amount of osteogenic material to be
added to the compositions of the present invention ranges from
about 0.001 to about 60% depending upon the material and preferably
about 0.001 to about 40% by weight. When used as Component 4, i.e.,
as an osteogenic material, it is preferred to use certain agents
such as DBM or mineralized bone in the form of larger average
particle sizes. Suitable larger average particle sizes are in the
range of about 0.05 to 10 mm preferably about 0.1 to 5 mm and most
preferably about 0.5 to 1 mm. However, the use of Component 4 in
smaller or larger particle sizes or in higher or lower amounts will
also be suitable if the requirements of the ultimate user are
satisfied.
[0069] With regard to the relative amounts of osteogenic material
to be used in a composition of the invention, one would use a bone
growth-inducing effective amount, by which is meant material
adequate in amount and average particle size to be osteoinductive
in the composition. The amount used may vary depending upon the
efficacy of the osteogenic agent and the average particle size of
the material. For example, growth factors such as BMP, Platelet
Derived Growth Factor (PDGF) and the like are effective in
fractional weight percent concentrations, whereas effective amounts
of DBM, mineralized bone matrix, and hydroxyapatite are usually in
higher weight percent concentrations, e.g., about 10% to about 50%
or higher, and preferably in somewhat larger average particle sizes
than those used in Component 1.
[0070] The addition of the bone growth-inducing material improves
not only the compositions of the invention, but also improves the
prior art hemostatic formulations to yield novel compositions
therewith. Such additions will render these hemostatic formulations
osteogenic as well. It is believed that the presence of the
osteogenic material will also improve osteoconductive properties
because the relatively large particles tend to "open up" the putty
structure, thus providing spaces into which induced bone may
proliferate.
[0071] The type of prior art hemostatic formulations which will
especially be improved by such addition are the ones disclosed in
U.S. Pat. Nos., 4,439,420 and 4,568,536 each of which is
incorporated herein by reference for all purposes. Thus, the
present specification and claims are to be read as though the
complete specification and claims of the aforementioned patents
were reproduced herein verbatim. For purposes of convenience, the
formulations of those patents may be generally characterized as
comprising an absorbable hemostatic composition for use in the
control of osseous hemorrhage, comprising: a component comprising a
biocompatible fatty acid salt, the cation of said fatty acid salt
being selected from the group consisting of calcium, magnesium,
zinc, aluminum, lithium and barium and a component comprising a
body absorbable biocompatible base selected from the group
consisting of ethylene oxide/propylene oxide block copolymers,
polyhydroxy compounds, polyethylene glycols and methoxypolyethylene
glycols, triglycerides and fatty acid esters, and an optional
absorption enhancing agent. Thus, in this aspect of the invention,
the bone growth-inducing materials are added to the above prior art
formulations to produce an osteogenic hemostatic material as well
as an osteoinductive bone defect filling material.
Other Optional Ingredients
[0072] To any of the compositions described supra, may be added a
pharmaceutically effective amount of an anti-infective agent,
either alone or bound to a substrate to slow its release.
Illustrative of such anti-infective materials are tetracycline,
vancomycin, cephalosporins, and aminoglycosides such as tobramycin
and gentamicin, alone or bound to collagen, for example, and
combinations of the foregoing, iodine, alone or as a PVP complex,
colloidal silver, silver salts, alone or bound to a carrier such as
gelatin, collagen, and the like.
[0073] Other materials, such as a blood clot-inducing agents, e.g.,
epinephrine, tannic acid, ferrous sulfate, and the double-sulfates
of a trivalent metal and a univalent metal such as potassium
aluminum sulfate and ammonium aluminum sulfate; anti-neoplastic
agents such as methotrexate, cis-platinum, doxorubicin, and
combinations thereof, radionuclides such as Strontium 89, and the
like; analgesics such as benzocaine, lidocaine, tetracaine,
fentanyl (a potent non-opioid), and the like, anti-inflammatory
substances such as the non-specific ibuprofen and aspirin, or the
COX-2 specific inhibitors such as rofecoxib and celeboxib;
radiopaque substances such as iodo, compounds, e.g., ethyl monoiodo
stearate available as Ethiodol.RTM. (Savage Laboratories), and
barium salts such as barium stearate, may be added in to the
formulations in amounts which are effective to achieve their
therapeutic or diagnostic purposes. Depending upon the
characteristics of the colorant selected, colorants such as gentian
violet, D&C Violet #2, and D&C Green #6 are suitable.
[0074] In some embodiments of the invention, it may be desirable to
intimately admix water with the compositions of the invention. The
presence of a small amount of water, of the order of up to ten
percent or more, aids in a variety of ways among which is changing
the tactile quality of the composition. In this regard, the
resulting compositions often impart a sensation of reduced
coarseness over what may have existed in the compositions without
the water addition. In some instances, it is desirable to provide a
putty-like formulation or a less dense non-putty formulation having
a cohesive strength less than that of a putty, such as a cream, a
paste, or other such materials as previously set forth herein,
based upon water or other aqueous liquids rather than on more
hydrophobic vehicles. Bulking agents such as the metal fatty acid
salts, e.g., calcium stearate and other non-wettable bulking agents
described herein, are not wetted by water and do not provide
putty-like (or less dense) compositions with water. We have found,
however, that the treatment of the bulking agent with a small
amount of surface-active material, e.g., lecithin, the
Pluronics.RTM. such as Pluronic L-35.RTM., renders the unwettable
bulking agent sufficiently wettable to enable the preparation of a
suitable fatty acid salt-water formulation when Component 2 is an
aqueous vehicle. Suitable aqueous vehicles are water, saline,
various biocompatible buffer solutions, various body fluids, such
as blood, serum, blood component concentrates, and the like.
[0075] While the above putties have less resistance to irrigation
compared with the putties prepared using more hydrophobic
materials, they have applications in bone defect repair where more
rapid disintegration of the implant is desired. Non-ionic,
cationic, and anionic surfactants are suitable, although virtually
any biocompatible surfactant may be used as exemplified by dodecyl
trimethyl ammonium chloride, sodium lauryl sulfate, nonoxynol-9,
the Tweens, e.g., polyoxyethylenesorbitan monolaurate, Tergitol-7,
i.e., sodium heptadecyl sulfate, and the antimicrobial surfactant,
1-lauryl-3-ethylbenzo-triazolium bromide, and the like.
Non-putty-like compositions, such as creams, pastes, and the like,
may be prepared by using additional quantities of water. This is
especially useful during surgical procedures when it is desired to
form a putty- or cream-like composition using blood instead of
water.
[0076] The foregoing discussion relating to the use of blood
clot-inducing agents in the present invention illustrates the
embodiment wherein the compositions are capable of chemical
hemostasis in use. That is, the addition of the styptic material to
the compositions of the present invention, whether those
compositions are mechanically hemostatic or not, yields
compositions having the ability to act as chemical hemostatic
materials. Thus, an already mechanically hemostatic putty can be
made more efficiently hemostatic by adding the blood clot-inducing
material. Similarly, a lower cohesive strength cream or paste,
which may lack significant mechanical hemostatic properties, can be
made hemostatic by the addition of the blood cloning material. An
example of the latter is the application of a thin layer of a
vasoconstrictor-modified paste of the invention to a bleeding
acetabulum in hip surgery.
[0077] The components described above, when added together in
suitable proportions, yield useful, putty-like and non-putty like
agents having, to varying degrees, many favorable characteristics.
Various combinations of the components may require different times
and temperatures in the preparation process in order for the
putty-like characteristics to develop. For example, some materials
such as finely divided hydroxyapatite may take longer than other
components to achieve the puny-like state. In general, the putty
like compositions of the present invention are absorbable within a
reasonable time, usually within 30 days although absorption times
may be extended to several months or longer for some applications.
They are moldable and shapeable by hand at ambient temperatures,
handle well in presence of blood, and are washable with saline.
They sometimes are tacky to the touch, but do not stick to any
great degree to surgical gloves, wet or dry. They can be radiation
sterilized when radiation-sensitive material such as DBM or certain
antibiotics are not present.
[0078] The actual proportions of the materials selected will vary
depending upon the materials themselves, the number of components
used, and the use desired for the final putty composition. The user
will be guided initially by the requirement for the desired
viscosity, cohesive strength, and consistency to be obtained, i.e.
compositions ranging from flowable liquid consistencies to
consistencies of creams, pastes, ointments, gels, and the like to
the more cohesive putty-like consistencies, while maintaining other
characteristics desired in the ultimate use of the component.
[0079] The compositions described in this specification, when used
surgically, must be sterile. All, except those noted below, are
radiation sterilizable using, for example, a standard cobalt-60
radiation source and a nominal dose of 25 kGy. Exceptions are
formulations containing radiation-sensitive additives such as
demineralized bone matrix, bone morphogenic protein, certain
antibiotics, unsaturated molecules such as oleic acid and the like.
When such materials are used, sterility may be achieved by
radiation-sterilizing the bulk putty-like material and aseptically
adding the sterile radiation-sensitive additive followed by aseptic
packaging.
[0080] The compositions described in this specification may be
sterile or sterilizable and may be packaged in several formats. The
packages themselves may be sterile or sterilizable. The
compositions may be packaged as an amorphous (i.e., shapeless or
having no definite shape) material such as a paste, cream, or
putty, or in the shape of its container. They may be shaped
generally as a parallelepiped or as a generally rounded form,
examples of the former being small brick-shapes or slabs (in the
shape of a stick of chewing gum), and examples of the latter being
cylindrical-shaped, egg-shaped, or spherical-shaped products.
Alternatively, when the application permits and the viscosity is
suitable, the product can be packaged in a syringe-like or
plunger-assisted dispenser expressible or extrudable through an
orifice of appropriate cross section and shape. A mechanical assist
device similar to that used for caulking may be included. Another
package contains the product in a squeezable, deformable tube such
as a toothpaste-type tube or a collapsible tube such as those used
in caulking applications, with an orifice shaped and sized to
dispense any suitable shape onto the surface to be treated. The
package may comprise an outer barrier as an overwrap, for example,
a peelable blister pouch, to allow aseptic delivery of the package
to the sterile field.
[0081] The present invention also contemplates methods of use of
the compositions of the invention. For example, one embodiment is
the method of mechanically controlling the bleeding of bone by the
application of an effective amount of any of the compositions of
the invention to bleeding bone, wherein the composition has a
sufficiently dense consistency, such as in the putty compositions
of the invention. In such a case, the composition is a mechanical
hemostatic tamponade.
[0082] Another embodiment of the method of use of the invention is
the method of chemically controlling the bleeding of bone by the
application of an effective amount of any of the compositions of
the invention, wherein the composition contains a blood
clot-inducing agent as heretofore set forth. In the case of
putties, the composition is a chemical hemostatic tamponade.
Mechanical hemostatic tamponades of the invention which also
comprise a clot-inducing agent will act as both a mechanical
hemostat and a chemical hemostat.
[0083] Another method of the invention is the method for inducing
the growth of bone in a bone defect by applying an effective amount
of any composition of the invention containing a bone
growth-inducing agent, to the affected area of bone, especially
when the composition includes a bone growth-inducing material such
as DBM, mineralized bone matrix, bone morphogenic protein,
hydroxyapatite, or the like.
[0084] Another method is the method for treating an infection in or
around a bone by applying an effective amount of any composition of
the invention containing an anti-infective agent, to the affected
area of bone to be treated.
[0085] Another method is the method for destroying cancer cells in
or around a bone by applying an effective amount of any composition
of the invention containing an anti-neoplastic agent, to the
affected area of bone which contains such cells.
[0086] Another method is the method for reducing pain from an area
in or around a bone by applying an effective amount of any
composition of the invention containing an analgesic agent, to the
affected area.
[0087] Another method is the method for controlling inflammation in
or around a bone by applying an effective amount of any composition
of the invention containing an anti-inflammatory agent, to the
affected area.
[0088] Another method is the method for assessing the status of an
area in bone to which an implant has been applied by applying an
effective amount of any composition of the invention containing a
radiopaque agent, to the affected area and thereafter
radiographically visualizing the area and making a determination of
the status of the area.
[0089] Another method is the method for rendering wettable any of
the bulking agents used in the invention which may be hydrophobic
by treating the bulking agent with a cationic, anionic, or
non-ionic surfactant and then making a water-based putty from the
treated bulking agent using any source of liquid such as water
itself, saline, or body fluids such as blood, serum, or the
like.
[0090] Those skilled in the art will be aware of the manner in
which the compositions are applied and the amount thereof. In some
applications, large amounts of the tamponade may be used while in
others only small amounts may be required or desired.
[0091] The methods and examples provided below are intended to more
fully describe preferred embodiments of the invention and to
demonstrate its advantages and applicability.
[0092] The following examples illustrate specific embodiments of
the present invention.
Example 1
[0093] In this example and in all subsequent examples, unless
otherwise indicated, the composition was prepared by mechanical
blending of all dry reagents first and thereafter adding gradually
any liquid reagents. The composition was "worked" with a spatula at
room temperature until the desired consistency was obtained. In
some cases, if the material needed additional ingredients to
improve the consistency, that material was added and the mixture
continually kneaded or "worked" until the desired putty-like
consistency was obtained. The components are presented in parts by
weight.
TABLE-US-00001 Component 1 Calcium stearate 4 g. Component 2
Tocopheryl acetate 3 g. Component 3 Gelatin 3 g.
[0094] The sample yielded a putty-like mass with excellent water
resistance, physical and hemostatic characteristics and water
resistance properties, i.e., it resisted strongly attempts at
washing it away under the force of flowing tap water.
Example 1a
[0095] By varying the proportion of the liquid components, the
compositions of the present invention can be rendered into states
of lower (i.e. more liquid) or higher (i.e. more rigid)
viscosities. Illustrative of a lowered viscosity formulation is the
following: to the putty formulation of Example 1 is added 3 g. of
acetyl triethyl citrate. The resulting product has a cream-like
consistency and may be applied, in appropriate circumstances, to
bone as a hemostatic agent or as a delivery agent for a variety of
additives such as drugs.
Example 2
[0096] Partial replacement of calcium stearate with bone
growth-inducing materials
a)
TABLE-US-00002 Component 1 Calcium stearate 3 g. Component 2
Tocopheryl acetate 3 g. Component 3 Gelatin 3 g. Component 4
Hydroxyapatite (6-12 micron particle size) 1 g.
[0097] The resulting product is a putty-like mass with properties
comparable to the product in Example 1. When a small amount of
gentian violet sufficient to impart a discriminating light violet
color is added to the above formulation, a colored product with the
characteristics of the product of Example 1 is obtained.
b) Complete Replacement of Calcium Stearate with
Hydroxyapatite.
TABLE-US-00003 Component 1 Hydroxyapatite (6-12 micron particle
size) 2 g. Component 2 Tocopheryl acetate 2.5 g. Component 3
Gelatin 2 g.
[0098] The composition was allowed to stand at room temperature for
72 hours yielding a product that had the characteristics of the
product of Example 1.
Example 3
TABLE-US-00004 [0099] Component 1 Aluminum Palmitate 5 g. Component
2 Tocopheryl acetate 3 g. Component 3 Gelatin 3 g.
[0100] The resulting product is a putty-like mass with properties
similar to those described for the product in Example 1.
Example 3 a), 3 b), 3 c)
[0101] The putty-like formulation of Example 3 is rendered into
less viscous compositions by modifying the Example 3 formulation as
follows:
TABLE-US-00005 Ex. 3 Ex. 3a Ex. 3b Ex. 3c Component 1 Aluminum
Palmitate 5 5 5 5 Component 2 Tocopheryl acetate 3 4 6 8 Component
3 Gelatin 3 0 0 0
Formulation 3a has the consistency of a soft putty. Formulation 3b
has the consistency of a thick cream much like cake icing.
Formulation 3c has the consistency of a slowly flowable composition
much like cold honey. Each of them can be applied to bone as a
hemostatic agent.
Example 4
TABLE-US-00006 [0102] Component 1 Calcium stearate 5 g. Component 2
Tocopheryl acetate 3 g. Component 3 Gelatin 3 g. Component 4 DBM 3
g.
[0103] The resulting product has in addition to hemostatic
properties of the product of Example 1, the additional property of
osteoconductivity.
Example 5
TABLE-US-00007 [0104] 5a. 5b. Component 1 Calcium stearate 2 g. 1.3
Component 2 Triethyl citrate 1.6 g. 0.98 Component 3 Triton .RTM. X
100 0 0.02
[0105] The resulting product 5a, was putty-like and had physical
characteristics similar to those of Example 1. Product 5b was also
putty-like and is more rapidly absorbable than 5a. Triton.RTM. X
100 is available from Dow Chemical Co., Midland, Mich.
Example 6
TABLE-US-00008 [0106] Component 1 Calcium stearate 4 g. Component 2
Triethyl citrate 3 g. Component 3 Gelatin 3 g.
[0107] The resulting product was putty-like and had physical
characteristics useful as a hemostat, but not preferred when
compared to the product of Example 5.
Example 7
TABLE-US-00009 [0108] Component 1 Calcium stearate 2 g. Component 2
Acetyl triethyl citrate 2 g.
[0109] The resulting product has excellent putty-like
characteristics and physical characteristics comparable to those of
Example 1.
Example 8
TABLE-US-00010 [0110] Component 1 Calcium stearate 0.5 g. Component
2 Triethyl citrate 1 g. Component 4 Hydroxyapatite 2 g.
[0111] There resulted a low viscosity injectable composition having
hemostatic properties.
Example 9
TABLE-US-00011 [0112] Component 1 Calcium stearate .5 g. Component
2 Tocopheryl acetate 2 g. Component 4 Hydroxyapatite 2 g.
[0113] There resulted a composition having excellent putty-like
characteristics and water resistance.
Example 10
TABLE-US-00012 [0114] Component 1 Hydroxyapatite 2 g. Component 2
Triethyl citrate 2.5 g.
[0115] There resulted a composition which is easily applied to
rough bone surfaces with good adhesion and filling
characteristics.
Example 11
TABLE-US-00013 [0116] Component 1 Calcium stearate 3 g. Component 2
Tocopheryl acetate 1.0 g. Component 2 Triethyl citrate 1.5 g.
Component 3 Gelatin 2 g.
[0117] The resulting product was a good material with putty-like
physical characteristics similar to those of Example 1 and somewhat
more sticky than that of Example 1.
Example 12
TABLE-US-00014 [0118] Component 1 Calcium stearate 4 g. Component 2
Lauric acid 4 g. Component 2 Tocopheryl acetate .5 g.
[0119] The calcium stearate was blended with melted lauric acid and
formed a good putty which, upon cooling, solidified. The solid was
then crushed and blended with the tocopherol to yield a good
putty.
[0120] The resulting product has a putty-like consistency at body
temperatures and a somewhat harder consistency at room
temperature.
Example 13
TABLE-US-00015 [0121] Component 1 Calcium stearate 4 g. Component 2
Triethyl citrate 4 g. Component 2 Lauric acid 4 g.
[0122] The resulting product was putty-like and had physical
characteristics similar to those of Example 1 and with somewhat
less cohesiveness.
Example 14
TABLE-US-00016 [0123] Component 1 Calcium stearate 2 g. Component 2
Dodecane 1 g.
[0124] The resulting product had good water resistance, was of
lower viscosity and compared well with the other physical
characteristics of Example 1.
Example 15
TABLE-US-00017 [0125] Component 1 Calcium stearate 2 g. Component 2
Octanol-1 1 g.
[0126] The resulting product was of lower viscosity and had
physical characteristics similar to those of Example 14 but
somewhat less cohesive.
Example 16
TABLE-US-00018 [0127] Component 1 Calcium stearate 2 g. Component 2
Diethyl succinate 2 g. Component 3 Gelatin 2 g.
[0128] The resulting product was a good putty similar to Example
1.
Example 17
TABLE-US-00019 [0129] Component 1 Calcium stearate 4 g. Component 2
Diethyl succinate 3 g.
[0130] The resulting product was a good putty which had improved
consistency over that of Example 16.
Example 18
TABLE-US-00020 [0131] Component 1 Calcium stearate 4 g. Component 2
Acetyl triethyl citrate 3 g. Component 3 Gelatin 3 g.
[0132] The resulting product was comparable to that obtained in
Example 1.
Example 19
TABLE-US-00021 [0133] Component 1 Aluminum palmitate 4 g. Component
2 Tocopheryl acetate .3 g. Component 2 Triethyl citrate 3 g.
[0134] The resulting product was a soft, somewhat translucent putty
with good water resistance and good hemostatic characteristics.
Example 20
TABLE-US-00022 [0135] Component 1 Calcium stearate 3 g. Component 2
Tocopheryl acetate 3 g. Component 3 Gelatin 3 g. Component 4
Demineralized bone matrix 1 g.
[0136] The resulting product is a putty-like mass with properties
comparable to the product in Example 1 and has osteogenic
properties as well.
Example 21
TABLE-US-00023 [0137] Component 1 Hydroxyapatite 3 g. Component 2
Tocopheryl acetate 3.5 g. Component 3 Gelatin 3 g.
[0138] In this example, the material initially was soft and oily
and lacked coherence. However, upon standing at room temperature
for 72 hours, an excellent putty with good water resistance formed.
Increasing the amount of tocopheryl acetate by an additional 3 g.
yields a paste having a coarseness attributable to the gelatin.
Example 22
TABLE-US-00024 [0139] Component 1 Calcium stearate 3 g. Component 2
Di-n-hexylether 2.5 g. Component 3 Gelatin 2 g.
[0140] The resulting product is putty-like and has good water
resistance and physical characteristics similar to those of Example
1.
Example 23
TABLE-US-00025 [0141] Component 1 Calcium stearate 3 g. Component 2
Di-n-pentylketone 2.5 g. Component 3 Gelatin 2 g.
[0142] The resulting product is putty-like and has good water
resistance and physical characteristics similar to those of Example
22.
Example 24
TABLE-US-00026 [0143] Component 1 Calcium stearate 3 g. Component 2
Tocopheryl acetate 3 g. Component 3 Bovine collagen (powdered) 3
g.
[0144] The resulting product is putty-like, has good water
resistance and physical characteristics similar to those of Example
23. In addition, the putty has a fibrous texture as a result of the
fibrous powdered collagen sponge additive present as the absorption
accelerant (Component 3).
Example 25
TABLE-US-00027 [0145] Component 1 Calcium stearate 3 g. Component 2
Tocopheryl acetate 3 g. Component 3 *Bovine collagen (powdered) 3
g. containing gentamicin sulfate. *CollatampG, available in
Europe
[0146] There results a hemostatic putty with anti-infective
properties.
Example 26
TABLE-US-00028 [0147] Component 1 Calcium stearate 4 g. Component 2
Tocopheryl acetate 3 g. Component 3 Gelatin 3 g. Anti-Infective
Gentamicin sulfate 120 mg.
[0148] Example 1 is repeated except that 120 mg. of gentamicin
sulfate is combined with the dry components before the tocopheryl
acetate is added to make a putty. This example demonstrates the
preparation of a putty with anti-infective properties.
Example 27
TABLE-US-00029 [0149] Component 1 Calcium stearate 4 g. Component 2
Tocopheryl acetate 3 g. Component 3 Gelatin 3 g.
[0150] Example 1 is repeated except that the gelatin is soaked in
2% aqueous silver nitrate for 2 hours at room temperature, washed
with two changes of distilled water and one of acetone and then
dried overnight. This preparation has anti-infective properties as
a result of the presence of silver/gelatin complexes.
Example 28
TABLE-US-00030 [0151] Component 1 Calcium stearate 4 g. Component 2
Tocopheryl acetate 3 g. Component 3 Gelatin 3 g.
[0152] Example 1 is repeated except that 10 mg of the gelatin is
incubated overnight in one ml. of an aqueous solution containing 10
micrograms of lyophilized human bone morphogenetic protein (BMP-2,
Sigma-Aldrich) followed by air-drying overnight. The damp gelatin
is washed with acetone to remove residual moisture and combined
with the remainder of the gelatin to prepare the putty having
osteogenic and hemostatic properties.
Example 29
TABLE-US-00031 [0153] Component 1 Calcium stearate 4 g. Component 2
Tocopheryl acetate 3 g. Component 3 Gelatin 3 g.
[0154] Example 1 is repeated except that 0.5 ml of Betadine.RTM.
(povidone-iodine, 10%; equivalent to 1% available iodine) was mixed
into 10 g. of the formed putty of Example 1. The mass turned to a
brown color and has anti-infective properties.
Example 30
TABLE-US-00032 [0155] Component 1 Micronized polylactic acid 3 g.
Component 2 Tocopheryl acetate 1.5 g.
[0156] The mixture formed an excellent putty with good water
resistance and properties comparable to the product in Example
1.
Example 31
[0157] The following composition is described in U.S. Pat. No.
4,439,420 as a preferred composition of about 40% calcium stearate,
30% dextran and 30% castor oil. If water is added, the preferred
composition is 38% calcium stearate, 28% dextran, 27% castor oil
and 7% water (all weights are weight percent). The composition was
prepared by mechanical mixing at ambient temperatures to avoid
possible degradation of heat-sensitive components.
TABLE-US-00033 Calcium stearate 4 g. Castor oil 3 g. Dextran 3
g.
[0158] The calcium stearate and dextran were dry blended in a 50 ml
glass beaker and the castor oil was added with stirring using a
spatula. After several minutes of "working" the mixture with the
spatula at room temperature, the consistency gradually changed. The
mixture became crumbly and, after further working, became
putty-like. The addition of a small amount of water (about 1 g.)
reduces the gritty nature of the dextran.
Example 32
[0159] The formulation in Example 31 was modified as indicated
below to make a novel, putty-like composition of the present
invention. The mass is an effective hemostat and is an effective
osteogenic bone defect filler.
TABLE-US-00034 Calcium stearate 2 g. Castor oil 1.5 g. Dextran 1.5
g. DBM (demineralized bone matrix) 1.5 g.
[0160] The purpose of this example is to show that DBM can be added
to the compositions described in U.S. Pat. No. 4,439,420 to obtain
a putty-like mass with osteogenic properties.
Example 33
TABLE-US-00035 [0161] Component 1 Aluminum Palmitate 5 g. Component
2 Tocopheryl acetate 3 g. Component 3 Gelatin 3 g. Additive
Methotrexate .2 g.
[0162] The now chemotherapeutic putty is packed into a bone defect
following surgical excision of a bone tumor.
Example 34
TABLE-US-00036 [0163] Component 1 Aluminum Palmitate 5 g. Component
2 Tocopheryl acetate 3 g. Component 3 Gelatin 3 g. Additive
Strontium 89 (as a salt)
[0164] The above formulation, when provided with radioactively
effective amounts of Strontium 89, yields a radiotherapeutic putty
as described in Example 33.
Example 35
TABLE-US-00037 [0165] Component 1 Pulverized Absorbable Phosphate
Glass 3 g. Component 2 Tocopheryl Acetate 1 g.
A crucible containing sodium dihydrogen phosphate hydrate was
heated for 4 hours at about 800 degrees C. and then rapidly cooled.
The resulting absorbable phosphorus glass mass then was broken up
with a hammer and the fragments pulverized to a fine powder in a
rotating ball mill for about 72 hours. The finely pulverized glass
(3 g.) was stirred with tocopheryl acetate (1.0 g.) until a
putty-like mass formed having good physical properties and water
resistance.
Example 36
TABLE-US-00038 [0166] Component 1 Calcium stearate 3 g. Component 2
Ethyl laurate 3 g. Component 4 Demineralized bone matrix 1 g.
[0167] The purpose of this example is to show that DBM can be added
to the compositions described in U.S. Pat. No. 4,439,420 to obtain
a putty-like mass with osteogenic properties.
Example 37
TABLE-US-00039 [0168] Component 1 Hydroxyapatite 3 g. Component 2
Isopropyl palmitate 3.5 g. Component 3 Gelatin 3 g.
[0169] Upon standing at room temperature for 72 hours, an excellent
putty with good water resistance comparable to that of Example 2 is
obtained.
Example 38
TABLE-US-00040 [0170] Component 1 Calcium Stearate 5 g. Component 2
Glycerol (USP) 15 g.
[0171] Three grams of calcium stearate were mixed with 3 gram
incremental quantities of glycerol until the mixture displayed a
cream-like consistency (total of 15 g. glycerol). At that stage, an
additional two grams of calcium stearate were blended into the
mixture to obtain a composition having the consistency and
appearance of well-beaten egg whites.
Example 39
TABLE-US-00041 [0172] Component 1 Calcium Stearate 1 g. Component 2
Tocopheryl acetate 1 g. Component 3 Glycerol .25 g.
[0173] There resulted a relatively soft putty with excellent water
resistance.
Example 40
TABLE-US-00042 [0174] Component 1 Sucrose (Confectioner's Sugar) 3
g. Component 2 Olive Oil 2 g.
[0175] This results in a relatively rigid putty which washes away
very easily and is useful where low water resistance is
desired.
Example 41
[0176] Three grams of the product from Example 38 above was mixed
with 0.75 ml. of deionized water containing 30 ppm of colloidal
silver (Source Naturals, Inc., Scotts Valley, Calif. 98006). The
resulting hemostatic cream became off-white in color, due to the
presence of the anti-microbial silver, and was somewhat less
viscous than the original cream.
Example 42
TABLE-US-00043 [0177] Component 1 Calcium Stearate 4 g. Component 2
Pluronic .RTM. L-35* 0.2 g (Molecular Wt. 1900) Component 12 Water
2 g * Pluronic 588310, Lot WPAW-502B, BASF, Corp. Mt. Olive, NJ
07828-1234
[0178] The ingredients are combined with stirring until a
putty-like mass results. The material is easily dispersed in excess
water.
Example 43
TABLE-US-00044 [0179] Component 1 Calcium Stearate 12.0 g.
Component 2 d,1-alpha Tocopheryl Acetate 7.5 g. Component 3 Soya
Lecithin Granules 1.3 g.
[0180] The calcium stearate and lecithin (Archer-Daniels-Midland
Ultralec P) were mixed dry and the tocopheryl acetate was then
added with vigorous stirring. A putty formed which had good water
resistance and handling properties, but which was slightly more
tacky than corresponding formulations containing gelatin instead of
lecithin.
Example 44
TABLE-US-00045 [0181] Component 1 calcium stearate 0.6 g. Component
1 potato starch* 3.8 g. Component 2 d,1-alpha tocopheryl acetate
1.6 g. *Razin International, Inc. 6527 Route 9 Howell, New Jersey
07731
[0182] The tocopheryl acetate and calcium stearate were mixed
together and the starch was then added. The mixture formed a soft,
white putty with good water resistance. To prevent the formation of
post-operative adhesions, it may be desirable to sterilize the
putty using 25 kGy of ionizing gamma radiation from a cobalt 60
source in order to degrade the starch. Alternatively, the starch
may be subjected to radiation degradation prior to formulating it
into the putty.
The following Examples 45-51 show putty compositions, prepared as
in Example 1, having good water resistance and incrementally
increasing absorbabilities from slowly absorbable to more rapidly
absorbable as the amount of gelatin is increased relative to the
amount of calcium salt.
TABLE-US-00046 Parts - Parts Ca salt Parts component 2 gelatin-%
EXAMPLE 45 12 Ca stearate 7.5 tocopheryl acetate 0 0 EXAMPLE 46 12
Ca stearate 7.5 tocopheryl acetate 2.0 10 EXAMPLE 47 12 Ca stearate
7.5 tocopheryl acetate 3.5 15 EXAMPLE 48 12 Ca stearate 7.5
tocopheryl acetate 5.0 20 EXAMPLE 49 12 Ca laurate 7.5 tocopheryl
acetate 4.5 20 EXAMPLE 50 12 Ca stearate 7.5 triethy citrate 4.5 20
EXAMPLE 51 0.6 Ca stearate 1.6 tocopheryl acetate 5.0 70 a)parts-
b)parts- % % EXAMPLE 52 Component 1 Ca stearate 3.4 31 2.35 21
Component 2 tocopheryl 3.2 29 2.21 20 acetate Component 3 Gelatin
4.4 40 3.04 28 (150 Bloom) Component 4 DBM 0 3.40 31 TOTAL 11.0
11.0
The resulting product has characteristics similar to the putty of
Example 53.
[0183] The gelatin in formulation a) is present at 40% by weight
and the composition has good putty consistency with good water
resistance and absorbability.
[0184] When it is desired to obtain a denser formulation that may
be used as a vehicle in anchoring pins or screws, such as pedicle
screws, to bone in orthopedic procedures, the foregoing formulation
a) may be modified by including therein large particle size bone
chips and applied to the appropriate bone site. Thus, when 31 parts
of DBM, particle size 1-5 mm, are added to 69 parts of formulation
a), formulation b) results, comprising 31% DBM and 28% gelatin. The
consistency is that of a thick, dense putty into which pins or
screws may be placed and anchored into adjoining bone. In time, the
osteogenic character of the formulation will allow bone growth
around the pins or screws thus permanently anchoring them to
adjoining bone structures.
Example 53
TABLE-US-00047 [0185] Component 1 Ca stearate 3.0 g Component 2
tocopheryl acetate 0.4 g Component 2 tributyl citrate 2.3 g
Component 3 gelatin 2.0 g
There resulted a putty having very good hemostatic and
absorbability characteristics.
Example 54
TABLE-US-00048 [0186] Component 1 Ca stearate 3.0 Component 2
tocopheryl acetate 0.4 Component 2 acetyl tributyl citrate 2.3
Component 3 gelatin 2.0
The resulting product has characteristics similar to the putty of
Example 53.
Example 56
TABLE-US-00049 [0187] Component 1 Calcium Stearate 2.0 g. Component
2 Tocopheryl acetate 1.5 g. Component 3 Pluronic .RTM. F-38* 2.0 g.
(Molecular Wt. 4700) *Product 583095, Lot WP1W-515B, BASF Corp.,
Mt. Olive, NJ 07828-1234
The Pluronic was provided as a "Pastille" and ground to a powder
before mixing. The mixture formed an excellent putty.
Example 57
TABLE-US-00050 [0188] Component 1 Calcium Stearate 4.0 g. Component
2 Pluronic .RTM. L-35 3.0 g. (Molecular Wt. 1900)
The Pluronic in this example was a viscous liquid and formed an
excellent putty. Because this Pluronic is water soluble, it was not
necessary to add an absorption accelerant. The foregoing Examples
are illustrative of specific embodiments of the present invention.
Other embodiments, within the scope of the present invention, may
be prepared by those skilled in the art as described in the
foregoing Specification.
* * * * *